Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15759102 | 0.95 | GNAI3 (0.51) | GNAI3GNAO1GNAI1KMT2AMAPT | |
| SCHEMBL9978409 | 0.85 | KMT2A (0.48) | KMT2AMAPTMEN1TDP1CES2 | |
| SCHEMBL28042801 | 0.82 | KMT2A (0.45) | L3MBTL1KMT2AMAPTMEN1TDP1 | |
| SCHEMBL19669166 | 0.82 | GNAI3 (0.44) | GNAI3GNAO1GNAI1NCF1 | |
| SCHEMBL11923446 | 0.80 | GNAI3 (0.41) | GNAI3GNAO1GNAI1NCF1 | |
| SCHEMBL20113022 | 0.80 | GNAI3 (0.42) | GNAI3GNAO1GNAI1NCF1 | |
| SCHEMBL18502834 | 0.80 | NCF1 (0.45) | GNAI3GNAO1GNAI1TDP1NCF1 | |
| SCHEMBL12817476 | 0.79 | GNAI3 (0.57) | GNAI3GNAO1GNAI1KMT2AMAPT | |
| SCHEMBL19312883 | 0.79 | GNAO1 (0.50) | GNAI3GNAO1GNAI1L3MBTL1KMT2A | |
| SCHEMBL2990381 | 0.79 | NAAA (0.53) | KMT2AMAPTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | GNAI3 2090/4885GNAO1 2331/4885GNAI1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.